Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CMBI: CSPC PHARMA Out-licensing Deals Could Be Sustainable Revenue Growth Engine; Rating Buy Kept
Recommend 2 Positive 6 Negative 1 |
||||
|
||||
|
CMBI published a research report covering CSPC PHARMA (01093.HK), which logged a 10.4% YoY decline in total revenue to RMB26 billion in 2025, under impact of volume-based procurement (VBP) and prescription controls. However, core domestic sales are bottoming out and are expected to stabilize in 2026. Meanwhile, the company has transformed into a global innovative pharmaceutical enterprise, continuously achieving out-licensing deals, which could become a sustainable revenue growth engine. On the back of a differentiated pipeline, the broker expected recurring business development income to juice long-term growth. CMBI forecast CSPC's net profits for 2026-28 to be RMB5.706 billion/ RMB5.62 billion/ RMB6.97 billion, respectively, compared to RMB3.876 billion in 2025. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
